Back
Prothena Corp PLC 10K Form
Buy
52
PRTA
Prothena Corp PLC
Last Price:
47.07
Seasonality Move:
14.53%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-08-06 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2020-05-06 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2020-03-03 | 10K | PRTA/Prothena Corp PLC Annual |
2019-11-05 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2019-08-06 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2019-05-07 | 10Q | PRTA/Prothena Corp PLC Quarterly |
Receive PRTA News And Ratings
See the #1 stock for the next 7 days that we like better than PRTA
PRTA Financial Statistics
Sales & Book Value
Annual Sales: | $53.91M |
---|---|
Cash Flow: | $-5.13M |
Price / Cash Flow: | 0 |
Annual Sales: | $11.94 |
Price / Book: | 3.98 |
Profitability
EPS (TTM): | -2.51000 |
---|---|
Net Income (TTM): | $-116.95M |
Gross Margin: | $0 |
Return on Equity: | -25% |
Return on Assets: | -19.15% |
Prothena Corp PLC Earnings Forecast
Key Prothena Corp PLC Financial Ratios
- The Gross Profit Margin over the past 5 years for PRTA is 0.00%.
- The Selling, General & Administrative Expenses for PRTA have been equal to 92.56% of Gross Profit Margin.
- The Research & Development expenses have been 251.46% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of PRTA is -216.94% of Total Revenues.
- Per Share Earnings over the last 13 years have been positive in 6 years.
Prothena Corp PLC Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Healthcare |
Current Symbol: | PRTA |
CUSIP: | G72800 |
Website: | prothena.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 14.34 |
Quick Ratio: | 14.17 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
PRTA Technical Analysis vs Fundamental Analysis
Buy
52
Prothena Corp PLC (PRTA)
is a Buy
Is Prothena Corp PLC a Buy or a Sell?
-
Prothena Corp PLC stock is rated a Buy
The current Prothena Corp PLC [PRTA] share price is $47.07. The Score for PRTA is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.